BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 2, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Neurology/psychiatric

Haisco Pharmaceutical divulges new GPR52 agonists

Jan. 5, 2026
Haisco Pharmaceutical Group Co. Ltd. has synthesized G protein-coupled receptor GPR52 agonists reported to be useful for the treatment of psychiatric disorders.
Read More
Illustration of Alzheimer’s in the brain.
Neurology/psychiatric

NAD+ homeostasis restoration reverses AD pathology

Jan. 5, 2026
No Comments
Researchers at Case Western Reserve University and their collaborators described the use of P7C3-A20, a compound that restores nicotinamide adenine dinucleotide (NAD+) homeostasis, as a potential strategy to reverse Alzheimer’s disease (AD) pathology in advanced Aβ- and tau-driven AD models.
Read More
Neurology/psychiatric

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

Jan. 5, 2026
No Comments
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive neurodegenerative disorder caused by a CAG repeat expansion mutation in the coding region of the ATXN2 gene, which encodes ataxin-2.
Read More
Illustration of man holding magnifying glass to human body model showing muscle anatomy
Neurology/psychiatric

SPAST-AAV9 gene therapy prevents hereditary spastic paraplegia symptoms

Dec. 31, 2025
No Comments
In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical School presented a silence-and-replace gene therapy strategy aiming to address both the gain-of-toxicity and loss-of-function components of the disease hereditary spastic paraplegia (HSP).
Read More
Illustration of human brain and dna
Neurology/psychiatric

Gene therapy restores SynGAP1 function, rescues epilepsy and behaviors

Dec. 31, 2025
No Comments
SYNGAP1-related disorders (SRDs) are rare neurodevelopmental conditions characterized by a wide range of symptoms, including intellectual disability, epilepsy, motor deficits and increased risk-taking behavior.
Read More
Icons representing scientific research
The year in review

Science in 2025: the best of the rest

Dec. 31, 2025
By Mar de Miguel and Anette Breindl
No Comments
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Read More
Neurology/psychiatric

New Nav1.8 blockers disclosed in Chengdu Easton Biopharmaceuticals patent

Dec. 30, 2025
Chengdu Easton Biopharmaceuticals Co. Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.
Read More
Neurology/psychiatric

Neurodawn Pharmaceutical divulges new PDE3A inhibitors

Dec. 30, 2025
Neurodawn Pharmaceutical Co. Ltd. has synthesized phosphodiesterase PDE3A inhibitors reported to be useful for the treatment of dementia and cerebrovascular disorders.
Read More
Demyelination of a neuron
Neurology/psychiatric

Apoptotic body-like liposomes restore immune tolerance in MS

Dec. 30, 2025
No Comments
Multiple sclerosis (MS) is a chronic immune-mediated disease characterized by the destruction of myelin sheaths, neuroaxonal damage, glial cell activation and formation of demyelinated plaques in the CNS. Since MS is considered a prototypic antigen-specific autoimmune disease, restoring immune tolerance to self-antigens is being explored as a therapeutic strategy.
Read More
Neurology/psychiatric

Neushen Therapeutics patents new OGA inhibitors

Dec. 29, 2025
Neushen Therapeutics Inc. has disclosed N-acetyl-β-D-glucosaminidase (O-GlcNAcase; OGA) inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Read More
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 2797 2798 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 1, 2026.
  • Art concept for Parkinson's disease

    Emerging therapeutic strategies for Parkinson’s at ADPD 2026

    BioWorld
    Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
  • Vials, syringes, and pills

    With improved technologies, biomarkers, failed drugs may come into their own

    BioWorld
    At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing